Trial Profile
A prospective, single arm Physician Initiated Trial (PIT) to assess safety and efficacy of Biolimus A9-Eluting Stent (BES) - BioMatrix flex: All-Comers including complex case sub-group
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 31 Aug 2016
Price :
$35
*
At a glance
- Drugs Umirolimus (Primary)
- Indications Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- 26 Jul 2013 New trial record